Contemporary methods of prevention and early detection of cervical cancer - a review of the literature

Authors

  • Ewelina Zygmunt Student Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin
  • Dariusz Chojeta Student Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin
  • Aleksandra Zimna Student Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin
  • Hubert Wróblewski Student Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin
  • Barbara Maziarz Student Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin
  • Halina Piecewicz-Szczęsna Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin

DOI:

https://doi.org/10.12775/JEHS.2020.10.07.017

Keywords

cervical carcinoma, Human papillomavirus (HPV) vaccination, cytology, prevention, early detection.

Abstract

Cervical carcinoma remains a significant health problem, despite the progressive fall in the mortality rate during the past 60 years. However, cervical carcinoma is still the most common cancer among women worldwide and the leading cancer cause of death in many countries.  The primary strategy to reduce the incidence and death rate from cervical carcinoma is screening by cervical cytology. The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. This study is a review of currently available methods of prevention and early detection of cervical cancer.

References

GLOBOCAN 2008; International Agency for Research on Cancer; http://globocan.iarc.fr/

https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf

http://onkologia.org.pl/nowotwory-szyjki-macicy-kobiet/

Parkin DM, Bray F, FerlayJ i wsp. GLOBOCAN 2002 Cancer incidence, mortality and prevalence wordwide. IARC Cancer Base; Lyon 2004

https://www.mp.pl/szczepienia/aktualnosci/223498,powszechne-szczepienia-przeciw-hpv-raczej-po-2022-roku

The Advisory Committee on Immunization Practices Expands Recommendations on HPV Vaccine, Leaves Some Decisions Up to Patients and Their Providers. June 28, 2019 Rene F. Najera

Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol. Rec., 2017; 92 (19): 241–268

Andrews N., Stowe J. Miller E.: No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine, 2017; 35 (13): 1729–1732

Brotherton J.M.L., Bloem P.N.: Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best. Pract. Res. Clin. Obstet. Gynaecol., 2018; 47: 42–58

Rekomendacje Zespołu Ekspertów Polskiego Towarzystwa Ginekologicznego dotyczące szczepienia przeciwko zakażeniom HPV. Ginekol Pol 2009, 80: 139-146.

https://www.cdc.gov/hpv/hcp/protecting-patients.html

Charakterystyka produktu leczniczego – szczepionki: Silgard (MSD 2006) oraz Cervarix (GlaxoSmithKline 2007).

https://szczepienia.pzh.gov.pl/szczepionki/hpv/5/#kto-nie-powinien-zostac-zaszczepiony-przeciw-zakazeniom-hpv

Arbyn M. European Guidelines for Quality Assurance in Cervical Cancer Screening. 20082nd ed, Luxembourg, Luxembourg: Office for Official Publications of the European Communities

The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. Nowakowski A, Cybulski M, Śliwczyński A, Chil A, Teter Z, Seroczyński P, Arbyn M, AnttilA BMC Cancer. 2015 Apr 14; 15():279.

Polskie Towarzystwo Ginekologiczne: Rekomendacje PTG dotyczące diagnostyki, profilaktyki i wczesnego wykrywania raka szyjki macicy. Gin Pol 2006; 77: 655–659.

Rajtar M. Badanie cytologiczne. Mag Piel Położ 2000; 9: 35-6

Prandi S, Beccati D, De Aloysio G, et al. Applicability of the Bethesda System 2001 to a public health setting. Cancer 2006; 108: 271-6.

Sikorski M. Zakażenia HPV – współczesne poglądy i praktyka. Termedia, Poznań 2008

Wytyczne postępowania klinicznego ACOG 2009 r. Medycyna Praktyczna – Ginekologia i położnictwo 2010;2: 11–12

Reksa D, Muszyńska A, Grotowska M, et al. Rak szyjki macicy – profilaktyka a świadomość społeczna. Fam Med Prim Care Rev 2006; 8: 740-2.

Castle P, Wacholder S, Sherman M, [et al.]. Absolute risk of a subsequent abnormal papamong oncogenic human papillomavirus DNA-positive, cytologically negative women.Cancer.2002, 95, 2145-2151.

Lynge E, Antilla A, Arbyn M et al. Wath’s next? Perspectives and future of cervical screening in Europe in the era of molecular testing and vaccination.European Journal of Cancer 2009; 45: 2714–2721.

Postępowanie w przypadku nieprawidłowego wyniku przesiewowego badania cytologicznego. Rekomendacje Centralnego Ośrodka Koordynującego Populacyjny Program Profilaktyki i Wczesnego Wykrywania Raka Szyjki Macicy, Polskiego Towarzystwa Ginekologicznego, Polskiego Towarzystwa Patologów i Polskiego Towarzystwa Kolposkopii i Patofizjologii Szyjki Macicy. Warszawa 20

Downloads

Published

2020-07-21

How to Cite

1.
ZYGMUNT, Ewelina, CHOJETA, Dariusz, ZIMNA, Aleksandra, WRÓBLEWSKI, Hubert, MAZIARZ, Barbara and PIECEWICZ-SZCZĘSNA, Halina. Contemporary methods of prevention and early detection of cervical cancer - a review of the literature. Journal of Education, Health and Sport. Online. 21 July 2020. Vol. 10, no. 7, pp. 173-179. [Accessed 13 January 2025]. DOI 10.12775/JEHS.2020.10.07.017.

Issue

Vol. 10 No. 7 (2020)

Section

Review Articles

License

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 661
Number of citations: 0